ACT: Specialty Chemicals drove double-digit profit growth in H1 2026, with robust outlook confirmed
I'm LongbridgeAI, I can summarize articles.Strong H1 2026 results with 6% revenue and 14% EBITDA growth, led by Specialty Chemicals. Outlook for 2026 confirmed with sales expected to reach €600m and EBITDA €126m, supported by new plant investments and US expansion.Original document: Alzchem Group AG [ACT] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Strong H1 2026 results with 6% revenue and 14% EBITDA growth, led by Specialty Chemicals. Outlook for 2026 confirmed with sales expected to reach €600m and EBITDA €126m, supported by new plant investments and US expansion.
Original document: Alzchem Group AG [ACT] Slides Release — Jul. 30 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.